cx-659s and Dermatitis--Allergic-Contact

cx-659s has been researched along with Dermatitis--Allergic-Contact* in 2 studies

Other Studies

2 other study(ies) available for cx-659s and Dermatitis--Allergic-Contact

ArticleYear
Protective and curative effects of topically applied CX-659S, a novel diaminouracil derivative, on chronic picryl chloride-induced contact hypersensitivity responses.
    The British journal of dermatology, 2002, Volume: 147, Issue:4

    CX-659S, a newly discovered anti-inflammatory compound, exerts inhibitory effects against acute contact hypersensitivity responses (CHRs) induced by picryl chloride (PC), oxazolone and dinitrochlorobenzene. The murine model of chronic CHR induced by repeated application of PC is known to mimic many, if not all, events occurring within the lesional skin of patients with atopic dermatitis (AD).. To investigate the ability of CX-659S to inhibit PC-induced chronic CHR in mice.. The protective and curative effects of CX-659S were tested on PC-treated ears of BALB/c mice, and were compared with those of prednisolone. Effects were quantified by measurements of ear thickness, serum IgE and cytokine mRNA expression.. Both protectively applied and curatively applied CX-659S significantly inhibited increases in ear thickness and total serum IgE. Inhibition was dose-dependent. Although protectively applied prednisolone showed similar activities to CX-659S against chronic CHR, curatively applied prednisolone did not affect the serum IgE level despite inhibiting increases in ear thickness and inflammatory cell infiltration. Consistent with these results, CX-659S reduced mRNA expression of interleukin (IL)-4 and IL-10 but not of interferon (IFN)-gamma, whereas prednisolone inhibited not only mRNA expression of IL-4 and IL-10 but also that of IFN-gamma in the ear lesion. In contrast to prednisolone, CX-659S did not show any side-effect such as atrophy, alopecia or telangiectasia.. CX-659S is the first promising compound having inhibitory activities against chronic CHR accompanied by a diminishing effect on elevated serum IgE, without any other side-effect. Therefore, CX-659S may be a promising candidate for management of patients with recurring AD who require long-term therapy.

    Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Chronic Disease; Cytokines; Dermatitis, Allergic Contact; Gene Expression Regulation; Glucocorticoids; Immunoglobulin E; Male; Mice; Mice, Inbred BALB C; Picryl Chloride; Prednisolone; RNA, Messenger; Uracil

2002
Synthesis and biological evaluation of CX-659S and its related compounds for their inhibitory effects on the delayed-type hypersensitivity reaction.
    Bioorganic & medicinal chemistry, 2000, Volume: 8, Issue:8

    In order to find novel nonsteroidal compounds possessing an inhibitory activity against delayed-type hypersensitivity (DTH) reactions, we conducted random screening using a picryl chloride (PC)-induced contact hypersensitivity reaction (CHR) in mice, and found compound 1 as a lead compound. Then we synthesized and evaluated an extensive series of 5-carboxamidouracil derivatives focused on both the uracil and the antioxidative moieties. Among them, we found that the hindered phenol moiety was necessary to exhibit the activities; especially, compounds 28a-28c having the partial structure of vitamin E were found to exert potent activities against the DTH reaction by both oral and topical administration. And compound 28c showed antioxidative activity against lipid peroxidation with an IC50 of 5.9 microM. Compound 28c (CX-659S) was chosen as a candidate drug for the treatment of cutaneous disorders such as atopic dermatitis and allergic contact dermatitis.

    Topics: Animals; Anti-Allergic Agents; Antioxidants; Brain Chemistry; Dermatitis, Allergic Contact; Drug Evaluation, Preclinical; Humans; Lipid Peroxidation; Male; Mice; Mice, Inbred ICR; Molecular Structure; Picryl Chloride; Random Allocation; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Uracil

2000